Dupont Capital Management Corp trimmed its position in Natera Inc (NASDAQ:NTRA) by 58.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,616 shares of the medical research company’s stock after selling 16,350 shares during the period. Dupont Capital Management Corp’s holdings in Natera were worth $278,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of NTRA. Pendal Group Ltd bought a new stake in Natera during the 3rd quarter valued at approximately $893,000. Zions Bancorporation bought a new stake in Natera during the 3rd quarter valued at approximately $6,319,000. Meeder Asset Management Inc. raised its stake in Natera by 920.5% during the 3rd quarter. Meeder Asset Management Inc. now owns 8,399 shares of the medical research company’s stock valued at $200,000 after purchasing an additional 7,576 shares during the period. Wells Fargo & Company MN raised its stake in Natera by 6.9% during the 3rd quarter. Wells Fargo & Company MN now owns 52,899 shares of the medical research company’s stock valued at $1,266,000 after purchasing an additional 3,411 shares during the period. Finally, Gilder Gagnon Howe & Co. LLC bought a new stake in Natera during the 3rd quarter valued at approximately $1,035,000. 80.39% of the stock is currently owned by institutional investors.

In related news, COO Steven Leonard Chapman sold 45,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 11th. The stock was sold at an average price of $25.16, for a total transaction of $1,132,200.00. Following the completion of the sale, the chief operating officer now directly owns 16,628 shares of the company’s stock, valued at approximately $418,360.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jonathan Sheena sold 166,667 shares of the firm’s stock in a transaction that occurred on Friday, September 14th. The stock was sold at an average price of $24.27, for a total value of $4,045,008.09. Following the sale, the insider now directly owns 481,975 shares of the company’s stock, valued at $11,697,533.25. The disclosure for this sale can be found here. Insiders have sold a total of 2,014,988 shares of company stock valued at $48,674,710 over the last three months. 13.18% of the stock is owned by corporate insiders.

Shares of Natera stock opened at $15.42 on Thursday. The company has a market capitalization of $957.03 million, a PE ratio of -6.43 and a beta of 2.11. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.44 and a quick ratio of 2.32. Natera Inc has a one year low of $8.60 and a one year high of $29.62.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, November 8th. The medical research company reported ($0.49) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.03). Natera had a negative return on equity of 2,569.52% and a negative net margin of 58.00%. The business had revenue of $65.30 million for the quarter, compared to the consensus estimate of $66.42 million. During the same period in the prior year, the business posted ($0.51) earnings per share. Natera’s revenue was up 16.8% on a year-over-year basis. As a group, research analysts forecast that Natera Inc will post -2.11 earnings per share for the current year.

Several equities analysts have weighed in on the company. JPMorgan Chase & Co. assumed coverage on Natera in a report on Friday, October 5th. They set a “neutral” rating and a $26.00 price target for the company. BidaskClub cut Natera from a “sell” rating to a “strong sell” rating in a report on Tuesday, November 13th. TheStreet cut Natera from a “c-” rating to a “d+” rating in a report on Tuesday, October 9th. Morgan Stanley raised their price target on Natera from $21.00 to $41.00 and gave the company an “overweight” rating in a report on Friday, September 28th. Finally, Zacks Investment Research cut Natera from a “buy” rating to a “hold” rating in a report on Wednesday, November 14th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $28.25.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.dailypolitical.com/2018/11/22/dupont-capital-management-corp-sells-16350-shares-of-natera-inc-ntra.html.

Natera Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Further Reading: What is the balance sheet?

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.